Axitinib, an orally pan-VEGFR inhibitor, was evaluated in a small cohort of 5 patients with advanced and metastatic CCA following the failure of first-line gemcitabine-based chemotherapy. This evidence concerns the gene KDR and cholangiocarcinoma.